The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 11, 2017
Filed:
Jan. 15, 2016
Applicant:
Celgene International Ii Sàrl, Couvet, CH;
Inventors:
Marcus F. Boehm, San Diego, CA (US);
Esther Martinborough, San Diego, CA (US);
Manisha Moorjani, San Diego, CA (US);
Junko Tamiya, Carlsbad, CA (US);
Liming Huang, San Diego, CA (US);
Thomas Fowler, Melton Mowbray, GB;
Andrew Novak, Long Eaton, GB;
Premji Meghani, Loughborough, GB;
Enugurthi Brahmachary, San Diego, CA (US);
Adam Richard Yeager, La Mesa, CA (US);
Assignee:
Celgene International II SÀRL, Couvet, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4245 (2006.01); A61K 9/00 (2006.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/40 (2006.01); A61K 47/48 (2006.01); A61K 45/06 (2006.01); A61K 31/155 (2006.01); A61K 38/26 (2006.01); C07C 255/57 (2006.01); C07D 213/79 (2006.01); C07D 213/80 (2006.01); C07D 213/81 (2006.01); C07D 213/82 (2006.01); C07D 309/06 (2006.01); C07D 309/08 (2006.01); C07D 311/16 (2006.01); C07C 271/28 (2006.01); C07D 215/48 (2006.01); C07D 217/02 (2006.01); C07C 275/42 (2006.01); C07D 317/68 (2006.01); C07D 231/12 (2006.01); C07D 333/38 (2006.01); C07D 233/60 (2006.01); C07C 311/08 (2006.01); C07C 311/13 (2006.01); C07C 311/21 (2006.01); C07D 235/06 (2006.01); C07C 311/29 (2006.01); C07D 235/12 (2006.01); C07D 235/18 (2006.01); C07C 311/48 (2006.01); C07D 239/26 (2006.01); C07D 239/28 (2006.01); C07C 317/28 (2006.01); C07C 317/44 (2006.01); C07D 239/74 (2006.01); C07D 413/04 (2006.01); C07D 239/91 (2006.01); C07D 413/12 (2006.01); C07D 241/42 (2006.01); C07D 241/44 (2006.01); C07D 417/12 (2006.01); C07C 323/62 (2006.01); C07C 229/14 (2006.01); C07D 249/08 (2006.01); C07D 257/04 (2006.01); C07C 233/47 (2006.01); C07C 233/51 (2006.01); C07D 261/18 (2006.01); C07C 233/81 (2006.01); C07C 233/83 (2006.01); C07C 235/12 (2006.01); C07D 263/32 (2006.01); C07C 235/38 (2006.01); C07D 263/34 (2006.01); C07C 235/48 (2006.01); C07D 263/48 (2006.01); C07D 263/57 (2006.01); C07C 237/22 (2006.01); C07C 237/36 (2006.01); C07C 237/42 (2006.01); C07D 271/06 (2006.01); C07D 271/07 (2006.01); C07D 271/107 (2006.01); C07D 207/267 (2006.01); C07D 277/30 (2006.01); C07D 209/08 (2006.01); C07D 277/56 (2006.01); C07D 277/66 (2006.01); C07D 279/12 (2006.01); C07D 211/14 (2006.01); C07D 211/34 (2006.01); C07D 211/62 (2006.01); C07D 295/15 (2006.01); C07D 295/155 (2006.01); C07D 295/205 (2006.01); C07D 213/55 (2006.01); C07D 213/65 (2006.01); C07D 307/24 (2006.01); C07D 307/54 (2006.01); C07D 307/68 (2006.01); C07D 307/79 (2006.01); C08B 37/16 (2006.01); C08L 5/16 (2006.01); B82Y 5/00 (2011.01); A61K 31/235 (2006.01); A61K 31/341 (2006.01); A61K 31/4406 (2006.01); A61K 31/4465 (2006.01); A61K 31/495 (2006.01); A61K 31/505 (2006.01); A61K 31/5375 (2006.01); A61K 31/54 (2006.01); C07D 295/24 (2006.01); A61K 31/4439 (2006.01); A61K 31/4725 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4245 (2013.01); A61K 9/0019 (2013.01); A61K 9/0095 (2013.01); A61K 31/155 (2013.01); A61K 31/235 (2013.01); A61K 31/341 (2013.01); A61K 31/4406 (2013.01); A61K 31/4439 (2013.01); A61K 31/4465 (2013.01); A61K 31/4725 (2013.01); A61K 31/495 (2013.01); A61K 31/505 (2013.01); A61K 31/5375 (2013.01); A61K 31/54 (2013.01); A61K 38/26 (2013.01); A61K 45/06 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61K 47/48969 (2013.01); B82Y 5/00 (2013.01); C07C 229/14 (2013.01); C07C 233/47 (2013.01); C07C 233/51 (2013.01); C07C 233/81 (2013.01); C07C 233/83 (2013.01); C07C 235/12 (2013.01); C07C 235/38 (2013.01); C07C 235/48 (2013.01); C07C 237/22 (2013.01); C07C 237/36 (2013.01); C07C 237/42 (2013.01); C07C 255/57 (2013.01); C07C 271/28 (2013.01); C07C 275/42 (2013.01); C07C 311/08 (2013.01); C07C 311/13 (2013.01); C07C 311/21 (2013.01); C07C 311/29 (2013.01); C07C 311/48 (2013.01); C07C 317/28 (2013.01); C07C 317/44 (2013.01); C07C 323/62 (2013.01); C07D 207/267 (2013.01); C07D 209/08 (2013.01); C07D 211/14 (2013.01); C07D 211/34 (2013.01); C07D 211/62 (2013.01); C07D 213/55 (2013.01); C07D 213/65 (2013.01); C07D 213/79 (2013.01); C07D 213/80 (2013.01); C07D 213/81 (2013.01); C07D 213/82 (2013.01); C07D 215/48 (2013.01); C07D 217/02 (2013.01); C07D 231/12 (2013.01); C07D 233/60 (2013.01); C07D 235/06 (2013.01); C07D 235/12 (2013.01); C07D 235/18 (2013.01); C07D 239/26 (2013.01); C07D 239/28 (2013.01); C07D 239/74 (2013.01); C07D 239/91 (2013.01); C07D 241/42 (2013.01); C07D 241/44 (2013.01); C07D 249/08 (2013.01); C07D 257/04 (2013.01); C07D 261/18 (2013.01); C07D 263/32 (2013.01); C07D 263/34 (2013.01); C07D 263/48 (2013.01); C07D 263/57 (2013.01); C07D 271/06 (2013.01); C07D 271/07 (2013.01); C07D 271/107 (2013.01); C07D 277/30 (2013.01); C07D 277/56 (2013.01); C07D 277/66 (2013.01); C07D 279/12 (2013.01); C07D 295/15 (2013.01); C07D 295/155 (2013.01); C07D 295/205 (2013.01); C07D 295/24 (2013.01); C07D 307/24 (2013.01); C07D 307/54 (2013.01); C07D 307/68 (2013.01); C07D 307/79 (2013.01); C07D 309/06 (2013.01); C07D 309/08 (2013.01); C07D 311/16 (2013.01); C07D 317/68 (2013.01); C07D 333/38 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C08B 37/0015 (2013.01); C08L 5/16 (2013.01); C07C 2101/04 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01);
Abstract
Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.